---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002942"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:13:18.479104+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MaxCyte reports preliminary FY2022 revenue $44.3M (+31% YoY); guides 2023 growth 21-26%

## Summary
- FY2022 total revenue ~$44.3M, up 31% from $33.9M in 2021; Q4 revenue ~$12.4M, up 22%.
- Installed base >600 instruments (vs >500 end 2021); 18 SPL partnerships at year-end, 19 after Jan 2023.
- 2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program-related revenue ~$6M.
- Potential pre-commercial milestones under SPLs >$1.55B; 16 licensed clinical programs in clinic.
- SPL program-related revenue in FY2022 was $4.6M vs $2.5M in 2021; Q4 included $1.9M.

## SEC filing metadata
- accession: 0001558370-23-002942
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837023002942/0001558370-23-002942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837023002942/mxct-20230306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002942
- JSON: https://secwatch.observer/filing/0001558370-23-002942.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.